Abstract: Objective To observe the short-term efficacy, adverse effect and quality of life of advanced lung adenocarcinoma patients treated by elemene combined with pemetrexed plus cisplatin chemotherapy. Methods A total of 60 advanced lung adenocarcinoma patients were randomly divided into the observation group and the control group ,30 cases in each group. The observation group was treated with elemene combined with pemetrexed plus cisplatin chemotherapy, while the control group was treated with pemetrexed plus cisplatin chemotherapy. To compare the short-term efficacy, adverse effect and quality of life between the two groups of patients. Results The objective response rate（40.0%）and disease control rate（70.0%）in the observation group were higher than those in the control group(respectively 33.3% and 56.7%),but the difference was not statistically significant（P＞0.05）. Grade-Ⅲ～Ⅳ nausea, vomiting and fatigue were significantly reduced in the observation group compared with the control group, and the difference was statistically significant (P＜0.05）. After treatment, evaluation grades of the body function, role function, emotional function, cognitive function, social function and total health status of the observation group were significantly higher than those of the control group (P＜0.05）. Conclusion There was no significant difference in the short-term efficacy of elemene combined with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma compared with the chemotherapy alone. However, the occurrence of adverse effects was significantly reduced, and the quality of life was improved significantly.